Clinical Trial Update: Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update assessing the safety and immunogenicity of CVI-VZV-001 in adults aged 50 and older with herpes zoster; the study is not yet recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• CVI-VZV-001

Snippet

Sponsor: CHA Vaccine Institute Co., Ltd. | Conditions: Herpes Zoster | Phase 2 | Status: NOT_YET_RECRUITING